Table 2.
Initial oral dose | Intravenous, very high dose or pulse therapy | Intra-articular injection | |||
---|---|---|---|---|---|
Low | Medium | High | |||
Arthritides | |||||
Gouty arthritis, acute | - | 2 | 2 | - | 2 |
Juvenile idiopathic arthritis | - | 1 | 1 | - | 1 |
Osteoarthritis | - | - | - | - | 1 |
Acute calcium pyrophosphate crystal arthritis | - | - | - | - | 2 |
Psoriatic arthritis | - | 1 | - | - | 2 |
Reactive arthritis | - | - | - | - | 1 |
Rheumatic fever | - | 1 | 1 | - | - |
Rheumatoid arthritis | 2 | 2 | 1 | 1 | 2 |
Collagen disorders | |||||
Dermatomyositis, polymyositis | - | - | 3 | 1 | - |
Mixed connective tissue disease | - | 1 | - | 1 | 1 |
Polymyalgia rheumatica | - | 3 | - | 1 | - |
Sjögren's syndrome, primary | - | - | 1 | - | - |
Systemic lupus erythematosus | - | 2 | 1 | 1 | - |
Systemic sclerosis | - | 1 | - | - | - |
Systemic vasculitides | |||||
In general | - | - | 3 | 1 | - |
Initial dose, the dose at the start of therapy, will often be decreased in time depending on disease activity: low, ≤7.5 mg prednisone equivalent/day; medium, >7.5 but≤30 mg prednisone equivalent/day; high, >30 but ≤100 mg prednisone equivalent/day; very high, >100 mg prednisone equivalent/day. -, rare use; 1, infrequent use, for therapy-resistant disease, complications, severe flare, major exacerbation, and for bridging the lag-time of recently started therapy; 2, frequently added to/used as the basic therapeutic strategy; 3, basic part of the therapeutic strategy. With permission from BMJ publishing group [129].